Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- The 53 most innovative companies in healthcare (Advisory Board)
- Delaying DOAC after colonoscopy: Weighing the risks (MDedge)
- Practice-changing takeaways from the 2026 Gut Microbiota Summit: A clinical reality check (MDLinx)
- ‘Phenomenal’ Tech May Boost Adenoma Detection in Colonoscopy (Medscape)
- CEO of America’s largest public hospital system says he’s ready to replace radiologists with AI (Radiology Business)
- OpenEvidence and Tandem Partner to Streamline Evidence-Based Prescribing and Prior Authorizations (Business Wire)
- Where GI training may fall short (Becker’s GI & Endoscopy)
- AI gut health startups are selling answers that science can’t back up (PitchBook)
